Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Clin Otolaryngol ; 45(5): 788-795, 2020 09.
Artigo em Inglês | MEDLINE | ID: mdl-32516473

RESUMO

OBJECTIVE: To characterise the role of VEGF, EG-VEGF and its receptors in the development and progression of HNC. DESIGN: Human serum and tissues samples were collected from healthy, epulis and HNC patients and used for ELISA assays and immunohistochemistry studies, respectively. SETTING: Ibn Rochd Hospital of Casablanca (Morocco), INSERM and University of Grenoble Alpes (France). PARTICIPANTS: We used serum from 64 patients with head and neck cancers and from 71 controls without general pathology. Tissues samples were collected from seven patients with OSCC and from seven patients with Epulis. MAIN OUTCOME MEASURES: We compared circulating VEGF and EG-VEGF in normal and HNC patients and determined the expression, localisation and quantification of VEGF, EG-VEGF and its receptors; PROKR1 and PROKR2 as well as Ki67, CD31 and CD34 in OSCC and Epulis patients. RESULTS: Both EG-VEGF and VEGF circulating levels were significantly decreased in the HNC (P < .01). OSCC patients expressed less EG-VEGF and VEGF proteins, higher PROKR1 and PROKR2 with no change in CD31 and CD34 levels. A significant increase in Ki67 was observed in OSCC. CONCLUSIONS: We demonstrated that circulating VEGF and EG-VEGF are downregulated in HNC patients and in OSCC tissue. EG-VEGF receptors were increased in OSCC, along with a stabilisation of two key markers of angiogenesis. These findings strongly suggest that downregulation of angiogenesis in HNC might explain its moderate metastatic feature.


Assuntos
Regulação para Baixo , Neoplasias de Cabeça e Pescoço/sangue , Fator A de Crescimento do Endotélio Vascular/biossíntese , Fator de Crescimento do Endotélio Vascular Derivado de Glândula Endócrina/biossíntese , Adulto , Biomarcadores Tumorais/biossíntese , Biomarcadores Tumorais/sangue , Progressão da Doença , Glândulas Endócrinas/metabolismo , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Imuno-Histoquímica , Masculino , Fator A de Crescimento do Endotélio Vascular/sangue , Fator de Crescimento do Endotélio Vascular Derivado de Glândula Endócrina/sangue , Adulto Jovem
2.
Cancer Biomark ; 21(2): 345-354, 2018 Feb 06.
Artigo em Inglês | MEDLINE | ID: mdl-29226856

RESUMO

BACKGROUND: The highest risk factor for mortality among malignant tumors is metastasis. Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) is an angiogenic factor which biological activity is mediated via two G protein-coupled receptors, prokineticin receptor1 (PROKR1) and PROKR2. Recent studies suggested that EG-VEGF expression is deregulated in multiple cancers including colorectal cancer (CRC). METHODS: Using distinctive CRC and peritoneal carcinomatosis (PC) cohorts and a corresponding control cohort, we determined the circulating levels of EG-VEGF and its in situ expression, and that of its related receptors. RESULTS: Circulating EG-VEGF levels were significantly increased in patients with metastatic PC compared to CRC and control patients (p< 0.05). Furthermore, according to clinicopathologic examinations, local EG-VEGF expression correlated with higher tumor and nodal stages (p< 0.001) of CRC. EG-VEGF and PROKR2 were highly expressed in colorectal primary lesions compared to positive controls. PROKR1 expression was lower and did not change in tumor specimens. Also, EG-VEGF and its receptor PROKR2 were differentially expressed in the colorectal primary lesions and in the control groups. CONCLUSION: Altogether these findings suggest that EG-VEGF/receptors system might be an important actor in the CRC progression into PC and might be involved in the ability of tumor cells to invade other organs. Circulating EG-VEGF could be proposed as a prognostic marker in human CRC and its progression into PC.


Assuntos
Neoplasias Colorretais/genética , Neoplasias Peritoneais/genética , Receptores Acoplados a Proteínas G/genética , Receptores de Peptídeos/genética , Fator de Crescimento do Endotélio Vascular Derivado de Glândula Endócrina/genética , Adolescente , Adulto , Idoso , Neoplasias Colorretais/metabolismo , Neoplasias Colorretais/patologia , Progressão da Doença , Feminino , Humanos , Imuno-Histoquímica , Masculino , Pessoa de Meia-Idade , Neoplasias Peritoneais/metabolismo , Neoplasias Peritoneais/patologia , Receptores Acoplados a Proteínas G/metabolismo , Receptores de Peptídeos/metabolismo , Fatores de Risco , Fator de Crescimento do Endotélio Vascular Derivado de Glândula Endócrina/metabolismo , Adulto Jovem
3.
Pan Afr Med J ; 27: 234, 2017.
Artigo em Francês | MEDLINE | ID: mdl-28979636

RESUMO

INTRODUCTION: Peritoneal carcinosis is characterized by ineluctably terminal diffuse spread of abdominal cancer. It is the sign of an advanced disease or a re-emerging disease most often associated with a dark prognosis. Approximately two thirds of all peritoneal carcinomas are of gastrointestinal origin and one third are of non-digestive origin. METHODS: We conducted a retrospective descriptive study between January 2008 and December 2010 in order to establish epidemiological features and risk factors of peritoneal carcinosis of gastrointestinal origin at the Ibn Rochd University hospital, Casablanca. RESULTS: Forty-seven cases of peritoneal carcinosis of gastrointestinal origin were recorded (22 women, 25 men), corresponding to a prevalence of 6.19% and to a mean number of 15.6 cases per year. Age was the major risk factor in our case series (with an average age of 55.55 ± 12.32 years). Even family history was a risk factor to consider. CONCLUSION: This study concluded that the major risk factors for peritoneal carcinosis of digestive origin are age and family history at the Ibn Rochd University hospital, Casablanca (2008-2010).


Assuntos
Carcinoma/epidemiologia , Neoplasias Gastrointestinais/epidemiologia , Neoplasias Peritoneais/epidemiologia , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Carcinoma/secundário , Saúde da Família , Feminino , Neoplasias Gastrointestinais/patologia , Hospitais Universitários , Humanos , Masculino , Pessoa de Meia-Idade , Marrocos/epidemiologia , Neoplasias Peritoneais/secundário , Prevalência , Prognóstico , Estudos Retrospectivos , Fatores de Risco , Adulto Jovem
4.
Clin Cancer Res ; 23(22): 7130-7140, 2017 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-28899975

RESUMO

Purpose: Choriocarcinoma (CC) is the most malignant gestational trophoblastic disease that often develops from complete hydatidiform moles (CHM). Neither the mechanism of CC development nor its progression is yet characterized. We recently identified endocrine gland-derived vascular endothelial growth factor (EG-VEGF) as a novel key placental growth factor that controls trophoblast proliferation and invasion. EG-VEGF acts via two receptors, PROKR1 and PROKR2. Here, we demonstrate that EG-VEGF receptors can be targeted for CC therapy.Experimental Design: Three approaches were used: (i) a clinical investigation comparing circulating EG-VEGF in control (n = 20) and in distinctive CHM (n = 38) and CC (n = 9) cohorts, (ii) an in vitro study investigating EG-VEGF effects on the CC cell line JEG3, and (iii) an in vivo study including the development of a novel CC mouse model, through a direct injection of JEG3-luciferase into the placenta of gravid SCID-mice.Results: Both placental and circulating EG-VEGF levels were increased in CHM and CC (×5) patients. EG-VEGF increased JEG3 proliferation, migration, and invasion in two-dimensional (2D) and three-dimensional (3D) culture systems. JEG3 injection in the placenta caused CC development with large metastases compared with their injection into the uterine horn. Treatment of the animal model with EG-VEGF receptor's antagonists significantly reduced tumor development and progression and preserved pregnancy. Antibody-array and immunohistological analyses further deciphered the mechanism of the antagonist's actions.Conclusions: Our work describes a novel preclinical animal model of CC and presents evidence that EG-VEGF receptors can be targeted for CC therapy. This may provide safe and less toxic therapeutic options compared with the currently used multi-agent chemotherapies. Clin Cancer Res; 23(22); 7130-40. ©2017 AACR.


Assuntos
Antineoplásicos/farmacologia , Coriocarcinoma/metabolismo , Coriocarcinoma/patologia , Fator de Crescimento do Endotélio Vascular Derivado de Glândula Endócrina/antagonistas & inibidores , Animais , Biomarcadores Tumorais , Linhagem Celular Tumoral , Transformação Celular Neoplásica/genética , Transformação Celular Neoplásica/metabolismo , Coriocarcinoma/tratamento farmacológico , Coriocarcinoma/mortalidade , Modelos Animais de Doenças , Progressão da Doença , Feminino , Expressão Gênica , Genes Reporter , Humanos , Camundongos , Terapia de Alvo Molecular , Prognóstico , Receptores Acoplados a Proteínas G/genética , Receptores Acoplados a Proteínas G/metabolismo , Receptores de Peptídeos/genética , Receptores de Peptídeos/metabolismo , Transdução de Sinais , Fator de Crescimento do Endotélio Vascular Derivado de Glândula Endócrina/sangue , Fator de Crescimento do Endotélio Vascular Derivado de Glândula Endócrina/metabolismo , Ensaios Antitumorais Modelo de Xenoenxerto
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...